Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Upper Tract Urothelial Carcinomas × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 1794 Neoplasms 1274 Carcinoma, Non-Small-Cell Lung 1150 Prostatic Neoplasms 966 Multiple Myeloma 743 Leukemia, Myeloid, Acute 662 Neoplasm Metastasis 624 Colorectal Neoplasms 619 Lung Neoplasms 600 Melanoma 587 Lymphoma 578 Leukemia 524 Lymphoma, Non-Hodgkin 503 Leukemia, Lymphocytic, Chronic, B-Cell 467 Ovarian Neoplasms 464 Pancreatic Neoplasms 444 Precursor Cell Lymphoblastic Leukemia-Lymphoma 421 Recurrence 410 Myelodysplastic Syndromes 367 Lymphoma, Follicular 365 Carcinoma, Renal Cell 362 Head and Neck Neoplasms 345 Glioblastoma 337 Brain Neoplasms 335 Lymphoma, Large B-Cell, Diffuse 327 Carcinoma, Hepatocellular 298 Hodgkin Disease 297 Squamous Cell Carcinoma of Head and Neck 271 Lymphoma, Mantle-Cell 270 Sarcoma 247

Interventions

infigratinib 1 Drug Evaluation 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04197986 2024-03-13

PROOF302

QED Therapeutics, a BridgeBio company

Phase 3 Terminated

39 enrolled 31 charts

Upper Tract Urothelial Carcinomas

Data powered by HemOnc (CC BY 4.0) Colophon ⚡